Core Viewpoint - The export of the HaiFu Knife® focused ultrasound tumor treatment system to Uruguay marks the expansion of this Chinese original large medical device to 34 countries and regions globally [1][2] Group 1: Product and Technology - The HaiFu Knife is designed for the treatment of various benign and malignant tumors, including uterine fibroids, adenomyosis, breast fibroadenomas, liver cancer, pancreatic cancer, and breast cancer [1] - Its core technology utilizes focused ultrasound to precisely target lesions within the body, achieving non-invasive treatment through mechanical, thermal, and cavitation effects, leading to irreversible coagulative necrosis of the lesions [1] - The technology is particularly beneficial in gynecological diseases, preserving the structure and function of organs, thus protecting women's fertility [1] Group 2: Market Expansion and Impact - The shipment to Uruguay represents the seventh HaiFu Knife in Latin America, with previous installations in Mexico, Cuba, Dominica, Venezuela, Colombia, and Argentina [1] - The establishment of the first HaiFu Center in Uruguay is expected to provide patients with access to internationally leading treatment technology [1][2] - The growth potential for the application of the HaiFu Knife in Latin America is significant, with expectations for safer and less invasive treatment options for patients [2] Group 3: Training and Development - Sixteen Uruguayan doctors and management personnel participated in a two-week professional training program in China, covering various medical fields including obstetrics, urology, surgery, oncology, and cardiology [2] - The goal of the training is to provide more treatment options for patients with benign and malignant tumors [2] Group 4: Global Impact - As of the end of 2024, the HaiFu Knife has treated over 320,000 patients with benign and malignant tumors worldwide [2]